Birch pollen allergy vaccine - Anergis

Drug Profile

Birch pollen allergy vaccine - Anergis

Alternative Names: AllerT; AllerT-Birch

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator University of Lausanne
  • Developer Anergis
  • Class Antiallergics; Peptide vaccines; Peptides; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis

Most Recent Events

  • 14 Jul 2016 Anergis initiates a phase II trial for Allergic rhinoconjunctivitis in Denmark (SC) (EudraCT2016-000076-23)
  • 26 Aug 2015 Phase-IIb development for Allergic rhinoconjunctivitis was completed in Europe
  • 01 May 2015 Anergis completes a phase II trial for Allergic rhinoconjunctivitis in Canada (NCT02271009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top